Liens utiles

Institut National du Cancer agence d'expertise sanitaire et scientifique en cancérologie

Nota Bene Cancer bulletin de veille bibliographique dans les divers domaines de la recherche sur les cancers

Onco Actu brèves sur le web anglophone

 

Tous les liens utiles

Accueil » La R&D d'Unicancer » Les publications de la R&D d'Unicancer » Les publications

Publications de la R&D d'Unicancer

2016

Mutational profile of metastatic breast cancers: a retrospective analysis

Lefebvre C et al., PLoS Med. 2016 Dec 27;13(12)

2016

What specifications for a centre or network of excellence in clinical research ?

Diebolt V et al., Thérapie (2016) 71, 51-57

2016

Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.

Piperno-Neumann S et al., Lancet Oncol. 2016 Aug;17(8):1070-80.

2016

The ENCCA-WP7 /EuroSarc /EEC /PROVABES /EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report

Kager L et al., Clin Sarcoma Res. 2016 Mar 16;6:3.

2016

Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial

P. J.A.M. Brouwers et al., Radiother Oncol. 2016 Jul;120(1):107-13.

2016

Breast cancer screening: On our way to the future [article in French]

Delaloge S et al., Bull Cancer. 2016 Jul 26.

2016

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F et al., N Engl J Med. 2016 Aug 25;375(8):717-29.

2016

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Bonnefoi H et al., Annals of Oncology 0: 1–6, 2016

2016

A Systematic Evaluation of Blood Serum and Plasma Pre-Analytics for Metabolomics Cohort Studies

Jobard E et al., Int. J. Mol. Sci. 2016, 17, 2035

2016

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F et al., Lancet Oncol. 2016 May;17(5):600-11